Medlab Clinical Limited Stock

Equities

MDC

AU000000MDC8

Biotechnology & Medical Research

Market Closed - Australian S.E. 03:04:48 2023-02-23 pm EST 5-day change 1st Jan Change
6.6 AUD -.--% Intraday chart for Medlab Clinical Limited -5.04% -.--%
Sales 2022 1.28M 837K Sales 2023 4.41M 2.88M Capitalization 15.07M 9.84M
Net income 2022 -7M -4.57M Net income 2023 -6M -3.92M EV / Sales 2022 9.63 x
Net cash position 2022 4.07M 2.66M Net cash position 2023 226K 148K EV / Sales 2023 3.37 x
P/E ratio 2022
-2.29 x
P/E ratio 2023
-2.22 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 56.26%
More Fundamentals * Assessed data
Dynamic Chart
3 years
6.45
Extreme 6.45
33.75
5 years
6.45
Extreme 6.45
84.00
10 years
6.45
Extreme 6.45
180.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 21-05-12
Chief Tech/Sci/R&D Officer - 22-06-30
Chief Tech/Sci/R&D Officer - 15-01-21
Members of the board TitleAgeSince
Director/Board Member - 23-03-05
More insiders
Medlab Clinical Limited (Medlab) is an Australia-based biotechnology company focused on the development and commercialization of a pharmaceutical delivery platform. The Company is investigating a range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas, including pain management, mental health, gut health, diabetes, and allergies. The Company’s drug candidates include NanaBis, NanoCBD and NanoCelle. Medlab’s pipeline comprises a range of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The Company's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use and NanoCBD for mental stress . The Company also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory.
More about the company

Annual profits - Rate of surprise